James Caruso Purchases 8,680 Shares of Cellectar Biosciences (NASDAQ:CLRB) Stock

Posted by Geri Gentry on May 11th, 2026

Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) CEO James Caruso bought 8,680 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average price of $2.88 per share, for a total transaction of $24,998.40. Following the completion of the purchase, the chief executive officer directly owned 20,318 shares in the company, valued at $58,515.84. The trade was a 74.58% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Cellectar Biosciences Trading Down 1.3%

CLRB traded down $0.04 during trading on Monday, hitting $3.06. The stock had a trading volume of 291,986 shares, compared to its average volume of 2,915,618. The firm has a market cap of $12.97 million, a PE ratio of -0.32 and a beta of 0.43. Cellectar Biosciences, Inc. has a 12 month low of $2.43 and a 12 month high of $20.60. The company has a 50 day simple moving average of $2.91 and a 200-day simple moving average of $3.17.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.66. As a group, sell-side analysts anticipate that Cellectar Biosciences, Inc. will post -1.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CLRB. Maxim Group upgraded Cellectar Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 price target on shares of Cellectar Biosciences in a research report on Tuesday, May 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.00.

Get Our Latest Report on CLRB

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Cellectar Biosciences by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 3,744 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Cellectar Biosciences during the third quarter worth about $60,000. XTX Topco Ltd bought a new position in Cellectar Biosciences during the fourth quarter valued at about $36,000. Dimensional Fund Advisors LP bought a new position in Cellectar Biosciences during the third quarter valued at about $73,000. Finally, Citadel Advisors LLC acquired a new position in Cellectar Biosciences in the 3rd quarter valued at approximately $104,000. Institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

(Get Free Report)

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.